Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Carlo Barone

3PUBLICATIONS
11CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

Sort by Publication Date:
|Feb 25, 2022
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies.

Anna Maria Rachiglio, Laura Forgione, Raffaella Pasquale

|Aug 27, 2021
Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients.

Paola Fuso, Mariantonietta Di Salvatore, Concetta Santonocito

|Jan 19, 2021
Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer.

Carlo Barone, Maria Di Bartolomeo, Sara Lonardi

Pageof 1

Frequent Collaborators

2 joint publications

Armando Orlandi

1 joint publications

Evaristo Maiello

1 joint publications

Gerardo Rosati

1 joint publications

Sara Lonardi

1 joint publications

Angela Damato

1 joint publications

Carmine Pinto

1 joint publications

Nicola Normanno

1 joint publications

Paola Fuso

1 joint publications

Mariantonietta Di Salvatore

1 joint publications

Nicola Nicolotti

Frequent Collaborators

2 joint publications

Armando Orlandi

1 joint publications

Evaristo Maiello

1 joint publications

Gerardo Rosati

1 joint publications

Sara Lonardi

Top Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on : Jul 17, 2019

6.2K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA <em>In Situ</em> Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA <em>In Situ</em> Hybridization

Published on : Jun 07, 2016

6.9K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on : Oct 17, 2025

547
See more related videos

Top Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on : Jul 17, 2019

6.2K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA <em>In Situ</em> Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA <em>In Situ</em> Hybridization

Published on : Jun 07, 2016

6.9K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on : Oct 17, 2025

547
See more related videos